Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study

Neurocase

Volumn 9, Issue 3, 2003, Pages 274-282

  Nahas, Ziad ^a   George, Mark S ^a   Horner, Michael D ^a   Markowitz, John S ^a   Li, Xingbao ^a   Lorberbaum, Jeffrey P ^a   Owens, Susan D ^a   McGurk, Susan ^b   DeVane, Lindsay ^a   Risch, S Craig ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cingulate; Cognition; Donepezil; fMRI; Prefrontal; Schizophrenia; Verbal fluency

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; LITHIUM SALT; OLANZAPINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM;

ADULT; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROENCEPHALOGRAM; FRONTAL LOBE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TASK PERFORMANCE; VERBALIZATION;

ADULT; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; INDANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MIDDLE AGED; OUTPATIENTS; PIPERIDINES; PLACEBOS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0042591639     PISSN: 13554794     EISSN: None     Source Type: Journal    
DOI: 10.1076/neur.9.3.274.15563     Document Type: Article

References (52)

1. Andreasen NC, Paradiso S, O'Leary DS. "Cognitive dysmetria" as an integrative theory of schizophrenia: A dysfunction in cortical-subcortical-cerebellar circuitry? Schizophrenia Bulletin 1998; 24(2): 203-18.
2. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination, 3rd Edn. Iowa City: AJA Associates, 1994.
3. Breir A, Schreiber JL, Dyer J, et al. National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Archives of General Psychiatry 1991; 48: 239-46.
4. Crespo-Facorro B, Paradiso S, Andreasen NC, O'Leary DS, Watkins GL, Boles LL, Hichwa RD. Recalling word lists reveals "cognitive dysmetria" in schizophrenia: A positron emission tomography study. American Journal of Psychiatry 1999; 156(3): 386-92.
5. Cummings JL. Cholinesterase inhibitors: A new class of psychotropic compounds. American Journal of Psychiatry 2000; 157: 4-15.
6. Curtis VA, Bullmore ET, Brammer MJ, Wright IC, Chir B, Williams SCR, Morris RG, Sharma TS, Murray RM, McGuire PK. Attenuated frontal activation during a verbal fluency task in patients with schizophrenia. American Journal of Psychiatry 1998; 155: 1056-63.
7. Curtis VA, Bullmore ET, Morris RG, Brammer MJ, Williams SC, Simmons A, Sharma T, Murray RM, McGuire PK. Attenuated frontal activation in schizophrenia may be task dependent. Schizophrenia Research 1999; 37(1): 35-44.
8. Dolan RJ, Fletcher P, Frith CD, et al. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 1996; 378: 180-2.
9. Dye SM, Spence SA, Bench CJ, Hirsch SR, Stefan MD, Sharma T, Grasby PM. No evidence for left superior temporal dysfunction in asymptomatic schizophrenia and bipolar disorder. British Journal of Psychiatry 1999; 175: 367-74.
10. Fletcher P, McKenna PJ, Friston KJ, Frith CD, Dolan RJ. Abnormal cingulate modulation of fronto-temporal connectivity in schizophrenia. Neuroimage 1999; 9(3): 337-42.
11. Friston KJ, Frith CD, Liddle PF. Investigating a network model of word generation with positron emission tomography. Proceedings of the Royal Society of London Series B Biological Sciences 1991; 244: 101-6.
12. Friston KJ, Herold S, Fletcher P. Abnormal fronto-temporal interaction in schizophrenia. In: Watson SJ, editor. Biology of Schizophrenia and Affective Diseases. New York, NY: Raven, 1995: 449-81.
13. Gaillard WD, Hertz-Pannier L, Mott SH, Barnett AS, LeBihan D, Theodore WH. Functional anatomy of cognitive development: fMRI of verbal fluency in children and adults. Neurology 2000; 54(1): 180-5.
14. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatric Clinic of North America 1995; 16: 295-312.
15. Goldman RS, Axelrod BN, Tandon R, Ribeiro SC, Craig K, Berent S. Neuropsychological prediction of treatment efficacy and one year outcome in schizophrenia. Psychopathology 1993; 26: 122-6.
16. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 1996; 153: 321-30.
17. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry 1997; 154(6): 799-804.
18. Green MF, Nuechterlein KH. Should schizophrenia be treated as a neurocognitive disorder? Schizophrenia Bulletin 1999; 25(2): 309-19.
19. Gur RE, Mozley PD, Resnick SM. Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia related to clinical features. Archives of General Psychiatry 1995; 52: 657-67.
20. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 1999; 96(23): 1342-7.
21. Ingvar DH. Serial aspects of language and speech related to prefrontal cortical activity. A selective review. Human Neurobiology 1983; 2(3): 177-89.
22. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. British Journal of Psychiatry Supplements 1989; 7: 59-67.
23. Kim JJ, Mohamed S, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. American Journal of Psychiatry 2000; 157: 542-8.
24. Kraeplin E. Dementia Praecox and Paraphrenia (Facsimile of 1919 Edition. Barclay RM, trans.). Hungtington, NY: Robert Kreiger, 1971.
25. Lehman A. Vocational rehabilitation in schizophrenia. Schizophrenia Bulletin 1995; 21: 645-56.
26. MacEwan GW, Ehmann TS, Khanbhai I, Wrixon C. Donepezil in schizophrenia - Is it helpful? An experimental design case study. Acta Psychiatrica Scandinavica 2001; 104(6): 469-72.
27. McCarthy RA, Warrington EJ. Auditory word comprehension. In: McCarthry RA, Warrington EJ, editors. Cognitive Neuropsychology - A Clinical Introduction. San Diego, CA: Academic Press, 1990: 122-51.
28. McGuire PK, Shah GM, Murray RM. Increased blood flow in Broca's area during auditory hallucinations in schizophrenia. Lancet 1993; 342(8873): 703-6.
29. Meller JD, Adachi N, Takei N, Cluckie A, Toone BK, Lishman WA. SPET study of verbal fluency in schizophrenia and epilepsy. British Journal of Psychiatry 1998; 173: 69-74.
30. Meltzer HY. Pre-clinical pharmacology of atypical drugs. A selective review. British Journal of Psychiatry 1996; 168 (Suppl 29): 23-31.
31. Meltzer HY, McGurk S. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999; 25(2): 233-55.
32. Middelton FA, Strick PL. Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function. Science 1991; 27: 119-44.
33. Mozley LH, Gur RC, Gur RE et al. Relationships between verbal memory performance and the cerebral distribution of fluorodeoxyglucose in patients with schizophrenia. Biological Psychiatry 1996; 40: 443-51.
34. Phelps EA, Hyder F, Blamire AM, Shulman RG. FMRI of the prefrontal cortex during overt verbal fluency. NeuroReport 1997; 8(2): 561-5.
35. Pihlajamaki M, Tanila H, Hanninen T, Kononen M, Laakso M, Partanen K, Soininen H, Aronen HJ. Verbal fluency activates the left medial temporal lobe: A functional magnetic resonance imaging study. Annals of Neurology 2000; 47(4): 470-6.
36. Purdon SE. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. Journal of Psychiatry and Neuroscience 2000; 25(2): 108-16.
37. Risch SC, McGurk S, Horner MD, Nahas Z. Owens SD, Molloy M, Gilliard C, Christie S, Markowitz JS, DeVane CL, Mintzer J, George MS. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates. Neurocase 2001; 7(2): 105-10.
38. Rollema H, Yi L, Schmidt AW, Zorn SH. Clozapine increases dopamine release in prefrontal cortex by 5-HT1c receptors. European Journal of Pharmacology 1997; 338: R3-R5.
39. Ruff RM, Crouch JA, Troster AI, Marshall LF, Buchsbaum MS, Lottenberg S, Somers LM. Selected cases of poor outcome following a minor brain trauma: Comparing neuropsychological and positron emission tomography assessment. Brain Injury 1994; 8(4): 297-308.
40. Sawagushi T, Goldman-Rackic PS. The role of D1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of Rhesus monkeys performing an oculomotor delayed-response task. Journal of Neurophysiology 1994; 71: 515-28.
41. Saykin AI, Shtasel DI, Gur RE, Kester DB, Moxley LH, Stafaniak P et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry 1994; 51(2): 124-31.
42. Schlosser R, Hutchinson M, Joseffer S, Rusinek H, Saarimaki A, Stevenson J et al. Functional magnetic resonance imaging of human brain activity in a verbal fluency task. Journal of Neurology, Neurosurgery and Psychiatry 1998; 64(4): 492-8.
43. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunder AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2000; 97(11): 6037-42.
44. Spence SA, Hirsch SR, Brooks DJ, Grasby PM. Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. British Journal of Psychiatry 1998; 172: 316-23.
45. Spence SA, Liddle PF, Stefan MD, Hellwell JSE, Sharma T, Friston KJ, Hirsch SR, Frith CD, Murray RM, Deakin JFW, Grasby PM. Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. Focal dysfunction and distributed disconnectivity reappraised. British Journal of Psychiatry 2000; 176: 52-60.
46. Stefanski R, Goldberg SR. Serotonin 5-HT2 receptor antagonists-potential in the treatment of psychiatric disorders. Drug Therapy 1997; 5: 388-409.
47. Stryjer R, Bar F, Strous RD, Baruch Y, Rabey JM. Donepezil management of schizophrenia with associated dementia. Journal of Clinical Psychopharmacology 2002; 22(2): 226-9.
48. Swanson CL Jr, Mozley LH, Gur RE. Positron emission tomography studies of cerebral metabolism and blood flow in schizophrenia. In: Kirshan KRR, Doraiswamy PM, editors. Brain Imaging in Clinical Psychiatry. New York: Marcel Dekker, 1997: 401-24.
49. Weinberger DR, Berman KF. Prefrontal function in schizophrenia: Confounds and controversies. Philosophical Transactions of the Royal Society of London Series B Biological Sciences 1996; 351(1346): 1495-503.
50. Weinberger DR, Berman KF, Daniel DG. Prefrontal cortex dysfunction in schizophrenia. In: Levin HS, Eisenberg HM, Benton AL, editors. Frontal Lobe Function and Dysfunction. New York: Oxford University Press, 1991: 275-87.
51. Woodard JL, Grafton ST, Votaw JR, Green RC, Dobraski ME, Hoffman JM. Compensatory recruitment of neural resources during overt rehearsal of word lists in Alzheimer's disease. Neuropsychology 1998; 12(4): 491-504.
52. Zhang W, Bymaster FP. Effects of olanzapine and other antipsychotics in receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 1999; 141: 267-78.